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Resistant hypertension is commonly found in everyday clinical practice. However, the risks of resistant hypertension, as well as
the beneﬁts of treatment and control of blood pressure in patients with resistanthypertension remain vaguely clariﬁed. Data from
small clinical studies and observational cohorts suggest that patients with resistant hypertension are at increased cardiovascular
risk, while control of blood pressure oﬀers substantial beneﬁts. It has to be noted however that data from appropriate large
randomizedstudiesaremissing,andresistanthypertensionremainsremarkablyunderstudied. Resistanthypertensionhasattracted
signiﬁcant scientiﬁc interest lately, as new therapeutic modalities become available. The interventional management of resistant
hypertension either by carotid baroreceptor stimulation or renal sympathetic denervation is currently under investigation with
promising preliminary results. This review presents available evidence regarding the beneﬁts of treatment and control of blood
pressure in patients with resistant hypertension and oﬀers a critical evaluation of existing data in this ﬁeld.
1.Introduction
Resistant hypertension is deﬁned as uncontrolled blood
pressure despite the use of optimal doses of three anti-
hypertensive medications, of which one is a diuretic [1].
Although this deﬁnition encompasses a large number of
patients, many of these patients can be controlled with more
careful adjustment of their regimen and implementation
of good practices. Several factors have been identiﬁed as
contributors to resistant hypertension: poor patient adher-
ence, physician inertia, inadequate doses or inappropriate
combinations of antihypertensive drugs, secondary forms
of hypertension, drug-induced hypertension, excess alcohol
intake, and volume overload [2]. Lifestyle modiﬁcations
including salt restriction are very important in these patients
[3]. Addressing some of the comorbid conditions, such
as sleep apnea, primary aldosteronism [4], or addition of
adjunct therapies such as spironolactone [5–11] can achieve
blood pressure control. However, many patients remain
uncontrolled despite the use of four, ﬁve, or six antihyper-
tensive drugs, especially in everyday clinical practice, outside
the “sterile” environment of clinical trials. It is surprising to
realize thatalthoughhypertension isamong themoststudied
diseases, resistant hypertension which denotes the most
severe,high-risk, and probablymore scientiﬁcally interesting
subgroup remains so much understudied.
Unfortunately, data regarding the natural history of
resistant hypertension is limited. Furthermore, the beneﬁts
of controlling blood pressure in patients with resistant
hypertension are vaguely clariﬁed, and it seems that they
will continue to remain as such, since it is unethical to
performarandomizedstudywithacontrolgroupofresistant
hypertensives that will remain untreated. Since direct data
is not available, only clinically meaningful assumptions can2 International Journal of Hypertension
be made based on indirect information and using common
sense. Therefore, for the purpose of this paper we’ll use data
from the past (before the era of antihypertensive therapy),
data from clinical studies involving patients with severe or
malignant hypertension, data from small clinical studies in
patients with resistant hypertension, and from subgroups of
patients included in large clinical trials.
This paper attempts to present available evidence regard-
ing the beneﬁts of treatment and control of resistant
hypertension, to highlight the signiﬁcant scarcity of data in
thispopulation,andtocriticallyevaluatetheuseofdatafrom
other hypertensive subgroups for extrapolation in resistant
hypertension.
2.Data onMalignant Hypertension:
Lessonsfromthe Past
The risks of resistant hypertension and the beneﬁts of its
management remind one of the story of malignant hyper-
tension. Although uncontrolled or resistant hypertension is
ad i ﬀerent entity from malignant hypertension, it is well
known that in the long term, untreated or uncontrolled
hypertension can lead to “accelerated/malignant” phase (VA
studies). The term malignant hypertension was introduced
by Volhard and Fahr in 1914 for patients with severe
hypertension and renal insuﬃciency [12]. The term was
abandoned until the landmark studies performed at Mayo
Clinic by Keith and Wagener. It was observed that the
prognosis of malignant hypertension was extremely grave.In
the ﬁrst study from Mayo Clinic, only 7 out of 81 patients
with malignant hypertension were still alive after the ﬁfty
months offollowup, while the averagelength oflife was eight
months [13]. Retinitis was highlighted as an essential part of
malignant hypertension andwassigniﬁcantly associatedwith
mortality; the average length of life in patients with Grade
I retinitis was 17 months and that of patients with Grade
IV retinitis was 2 months. In a later study of 146 patients,
only 1 patient was alive at the end of ﬁve-year follow-up
period [14]. Further reports of more than 1400 patients
with malignant hypertension have conﬁrmed the ﬁndings
of Mayo Clinic and revealed that the ﬁve-year mortality
was over 90%, even until the 60s [15–18]. It’s worth noting
that no therapy was available at that time. Protein and salt
restriction, the rice diet, and mild sedatives were used for
the treatment of hypertension; however, the results were
all but hopeless regarding long-term improvements [19–
23]. Therefore, other therapeutic approaches for malignant
hypertension were considered.
Experimental and human studies have revealed the
central role of SNS in the pathogenesis of arterial hyper-
tension. Due to the lack of eﬀective therapeutic measures
for malignant hypertension, sympathectomy was proposed
by many physiologists, such as Pende, Danielopolu, and
Jonnesco. Sympathectomy was tested up, that point, for
the management of peripheral vascular disease (Jaboulay
and Leriche in France), angina pectoris (Jonnesco and
Danielopolu in Romania), spastic paralysis (Royle and
HunterinAustralia), and Raynaud’s disease and scleroderma
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Figure 1: Five-year mortality rates (%) in untreated patients with
malignant hypertension and Grade III or IV retinopathy compared
to similar patients that underwent sympathectomy (modiﬁed from
Keith et al. [25] and Peet et al. [26]).
in Germany (Bruening). Sympathectomy for the treatment
of malignant hypertension appears to have taken place for
the ﬁrst time in Germany as early as 1923 [24]. It was
introduced in the USby Alfred Adson atthe MayoClinicand
by Max Peet at Ann Arbor. It was rapidly realized that sym-
pathectomy dramatically increased the survival of patients
with malignant hypertension. The ﬁve-year mortality rates
of patients with Grade IV retinopathy fell from 99% at the
Keith Wagenerseries to 66.5%insympathectomized patients
[25, 26]; similar impressive improvements were observed in
patients with Grade III retinopathy (Figure 1).
The pioneer work of Peet, Adson Crile, Hener, Page,
Grimson, Hinton, and others was reinforced by Reginald
Smithwick, who established the operation worldwide as an
eﬀective method of lowering blood pressure in patients with
malignant hypertension. Until 1960, a plethora of papers
reported the eﬀects of sympathectomy in several thousand
patients with malignant hypertension all overthe world [27–
38],pointing towards dramatic improvementsinthesurvival
of operated patients [39] when compared to conservative
management (Figure 2).
The indications for sympathectomy waxed and waned
during this period. The operation was initially reserved for
patients with severe hypertension without signiﬁcant target
organ damage (heart failure, chronic renal disease, angina),
was later performed irrespective of the organ damage, and
ﬁnally restricted to patients without chronic complications
s i n c et h eb e n e ﬁ t sw e r em o r ea p p a r e n ti ns u c hp a t i e n t s .
Similarly, the extent of the operation varied between the
diﬀerent centers, due to the incomplete understanding of
sympathetic anatomy and the absence of appropriate studies
comparing the various surgical approaches. The common
denominator of all operating techniques was the need
for prolonged hospitalization and long recovery period.
Another annoying aspect of sympathectomy was the lack
of satisfactory predictors of blood pressure response to the
operation. Although several tests have been used, the results
were inconclusive and sometimes misleading.
The most important limitation of sympathectomy was
the safety of the procedure. Adverse events were frequentInternational Journal of Hypertension 3
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Figure 2: Survival rates in patients with malignant hypertension
at various stages (Group 1–4) treated either medically or surgically
(modiﬁed from Smithwickand Thompson [39]).
and annoying, such as orthostatic hypotension, periop-
erative pain, orthostatic tachycardia, anhidrosis, intestinal
and sexual problems, and palpitations, while more serious
complications have been reported, such a perioperative
death, stroke, myocardial infarction, paraplegia, and spinal
cord injury. The operation was unpleasant and intolerant
and many hypertension experts remained skeptical;Ed Weiss
stated in 1937 “... and now to cap the climax of his
diﬃculties the unfortunate person with hypertension seems
about to fall into the clutches of the neurosurgeon who
is prepared to separate him from his sympathetic nervous
system”, while Homer Smith used the words “investigation
and desperation” for sympathectomy. It was not until
the introduction of eﬀective antihypertensive drug therapy
that the beneﬁts and risks of sympathectomy were fully
reevaluated.
The interest in sympathectomy faded quite suddenly
with the advent of antihypertensive therapy. Centrally acting
drugs (ganglion-blocking agents, reserpine) have oﬀered
similar beneﬁcial eﬀects [40]( Figure 3). The introduction
of diuretics has closed the circle of sympathectomy in the
treatment of hypertension, highlighting that therapeutic
options fade away when new, more promising treatments
appear. Of note, blood pressure control signiﬁcantly aﬀected
the survival of treated patients [40]( Figure 4), underlining
that uncontrolled hypertension is associated with increased
mortality rates.
3.Data fromTrialsinSevereHypertension:
TheVAStudy
Despite the impressive beneﬁts of antihypertensive drugs
that have established their use in the treatment of malignant
hypertension, their role in the treatment of milder forms of
hypertension remained controversial for a signiﬁcant period
of time. Even in 1966, it was stated in the book Controversy
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Figure 3: Survival rates in untreated and medically treated patients
withmalignanthypertension(modiﬁedfromHaringtonetal.[40]).
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Figure 4: Survival rates in medically treated patients with malig-
nant hypertension according to blood pressure control (modiﬁed
from Harington et al. [40]).
in Internal Medicine that drug treatment of essential hyper-
tension was not beneﬁcial [41]. Several reasons contributed
to the “resistance” of hypertension specialists, primary care
physicians, and relevant authorities to recognize the beneﬁts
of antihypertensive therapy. Those beneﬁts include the
following.
(a) The general belief that vascular changes represent a
primary pathologic process that is independent of
blood pressure levels. Hypertension was considered
to bemerely a symptom and not thecause ofvascular4 International Journal of Hypertension
complications, therefore the motto “treat the patient,
not the manometer” was adopted by the majority.
(b) The inheritance of Sir William Osler promoted
therapeuticnihilism. The nihilistic attituderegarding
the role of drug therapy may be attributed to Osler’s
quote: “one of the ﬁrst duties of the physician is
to educate the masses not to take medicine” [42].
However, this was probably a misinterpretation of
Osler’s beliefs, since Osler was referring to the drugs
availableathistime,theuseofwhichreachedthelim-
its of charlatanism, and not modern antihypertensive
drugs that were not available at his time.
(c) The special emphasis and the exaggerated focus that
were given in secondary forms of hypertension, the
prevalence of which was largely overestimated and
absorbed the vast majority of available grants. The
opinion that one has to ﬁnd the cause before treating
the disease has prevailed, thus rendering “empiric”
antihypertensive therapy “a shot in the dark”, an
approach that was not appreciated at all. However,
the cause of hypertension remained unknown for the
vast majority of patients, and it was not unusual for
such patients to remain untreated.
(d) The role of preventive medicine was not considered
crucial and had not gained wide popularity at that
time. Patients, physicians, and the media were not
stuck by the beneﬁts of prevention, since the whole
society was not ready to move from therapy to
prevention.
(e) Maybe the most important factor that restricted the
wide adoptionof antihypertensive drugs was the lack
of convincing clinical studies to verify the beneﬁts of
treating essential hypertension.
The ﬁrst organized data demonstrating beneﬁt from the
treatment of severe hypertension came from the Veterans
Administration study group.UndertheleadershipofEdward
Freis the ﬁrst placebo controlled study was carried out in
patients with severe hypertension. In that study (published
in 1967), 143 patients with severe untreated hypertension
(diastolic>115mmHg) were randomized toeithertreatment
or placebo [43]. In only 20 months, it became apparent
that treatment of these patients with severe blood pressure
elevation was dramatically beneﬁcial. Twenty-six events
occurred in the placebo arm and only 1 in the treated
arm (Table 1). It is important to note that 12 out of 26
events were accelerated hypertension leading to malignant
hypertension. Since then, the standard of care is to treat
severe hypertension; it is unlikely that the study will be
repeated. Although the study was placebo controlled, it
is reasonable to assume that even treated patients who
remain with severe blood pressure elevations (i.e., resistant
to treatment) will have similarly bad prognosis.
Conﬁrmation of this assumption comes from many
longitudinal studies, cohorts, or subgroup analyses. In the
Australian National Blood Pressure study, early in the
antihypertensive therapy era, it was shown that patients with
uncontrolled blood pressure despite triple therapy had a
Table 1: Fatal and nonfatal events at the VA trial in patients with
severe hypertension receiving active treatment (HCTZ, reserpine,
and hydralazine) or placebo (modiﬁed from the VA collaborators
[43]).
Events Active treatment
n = 73
Placebo
n = 70
Deaths 04
Stroke 14
Coronary events 02
Heart failure 02
Renal damage 02
Accelerated hypertension 01 2
four-fold increased risk for cardiovascular events compared
to patients with controlled blood pressure [44–46].
4.Data fromSmall ClinicalStudies
Virtually no longitudinal study has addressed the particular
prognosis of resistant hypertension. Relevant information
may be extracted only from small clinical studies. Isakson
and Ostergren studied 36 patients with resistant hyperten-
sion in Sweden for a 7-year follow-up period [47]. For
each of these patients, two control patients were randomly
selected from a reference group (retrospectively, matched
for age and gender), and the outcomes of the two groups
were compared. It has been shown that patients with
resistant hypertension had an almost 3-fold increased risk
for cardiovascular events (stroke, transient ischemic attacks,
myocardial infarction, death, heart failure, renal failure,
new onset diabetes) compared to patients with controlled
hypertension (odds ratio 2.71; P<. 05).
Redon conducted, in Spain, a prospective study of 86
patientswith resistant hypertension (diastolicbloodpressure
>100mmHg) and a long follow-up period (49 months
average) using ambulatory blood pressure measurement
(ABPM) [48]. It was reported that patients with poorly
controlled blood pressure (daytime diastolic blood pressure
>97mmHg) had more than 6 times higher relative risk for
morbid cardiovascular events (relative risk: 6.42; 95% CI:
1.39–29.7; P = .017) compared to patients with relatively
controlled blood pressure (daytime diastolic blood pressure
<88mmHg) (Figure 5). It should be noted, however, that
the number of patients and events were relatively small,
oﬃce blood pressure was not independently associated with
morbid events, data regarding systolic blood pressure were
not provided, and the cut-oﬀ limit of daytime diastolic
bloodpressure (88mmHg) washigher than what iscurrently
considered normal (85mmHg).
PierdomenicoinItalystudiedalargernumberofpatients
(130 resistant hypertensives) for a slightly longer follow-up
period(4.98 ±2.9years)usingABPMaswell [49].Moreover,
the study compared the outcomes of patients with true
resistant hypertension (high clinic and ambulatory blood
pressure) to the outcomes of patients with false resistant
hypertension (high clinic and normal ambulatory bloodInternational Journal of Hypertension 5
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Figure 5: Probability of event-free survival in patients with
resistanthypertensionaccordingtodaytimediastolicbloodpressure
(modiﬁed from Redon et al. [48]).
pressure) and controlled hypertension (normal clinic and
ambulatory blood pressure). It was shown that patients with
true resistant hypertension had an almost 3-fold increased
relativerisk forcardiovascularevents(relativerisk: 2.94;95%
CI: 1.02–8.41; P<. 05) compared to patients with controlled
blood pressure.
More recently, Salles in Brazil studied an even larger
number of patients with resistant hypertension (556
patients) for a median follow-up period of 4.8 years [50]. It
was reported that resistant hypertension was an independent
predictor for cardiovascular and all-cause mortality. More-
over, it was shown that patients with resistant hypertension
had increased cardiovascular and all-cause mortality com-
pared to patients with false resistant hypertension (hazard
ratio: 2.30; 95% CI: 1.42–3.74). Recent studies from the
same group have shown the prognostic value of nocturnal
blood pressure, the ambulatory arterial stiﬀness index, the
electrocardiographic strain, and the ventricular repolariza-
tion in patients with resistant hypertension [51–54]. The
above ﬁndings along with the superiority of ambulatory
over oﬃce blood pressure measurements in patients with
resistant hypertension underline the importance of taking
into account other factors, beyond oﬃce blood pressure, in
the management of patients with resistant hypertension.
Magnanini studied 382 Brazilian women with resistant
hypertension and found that cardiovascular events (death,
ischemic heart disease, stroke, nephropathy) were higher
in patients with uncontrolled hypertension, as compared
to those with controlled blood pressure (5.8 versus 3.7
per 100 women/years, resp.), although the diﬀerence did
not reach statistical signiﬁcance (P = .06) [55]. However,
daytime blood pressure was found to be an independent risk
predictor (relative risk: 1.67; 95% CI: 1.00–2.78; P<. 05).
5.Data fromLargeClinicalTrials
The lack of reliable data regarding the outcome of uncon-
trolled versus controlled blood pressure in patients with
resistant hypertension using hard endpoints justiﬁes other
approaches. Onecanusedatafromotherpatientpopulations
and make rational assumptions, although extrapolation
carries inherent risks and has severe limitations.
For example, in a large cohort of hypertensive males
(4,714 patients), it has been shown that cardiovascular
mortality was almost twice as high in male patients with
uncontrolled hypertension compared to patients with well-
controlled blood pressure (risk ratio: 1.66; 95% CI: 1.04–
2.64), although particular data regarding resistant hyper-
tension are not provided [56]. In another cohort of 11,912
veteran male patients followed for 15 years, uncontrolled
hypertension (systolic blood pressure >150mmHg) was
associated with increased risk of end-stage renal disease
(risk ratio: 3.00; 95% CI: 2.09–4.55; P < .001) [57]. Is this
exaggerated cardiovascular risk of uncontrolled hyperten-
sion applicable in resistant hypertension? Common sense
dictates that there is no reason to assume the opposite.
Until convincing data becomes available, it seems clinically
wise to assume that controlling blood pressure in resistant
hypertension is beneﬁcial, and treating physicians should
make every possible eﬀort towards this direction.
Relevant information can be obtained from large clinical
trials. Although no trial has been speciﬁcally designed to
evaluate the beneﬁts of blood pressure control in resistant
hypertension, data from recent large trials regarding patients
that fulﬁll the deﬁnition of resistant hypertension will be
valuable until the conduction of a study devoted to resistant
hypertension. We have to keep in mind, however, the
inherentlimitationsofsuchstudies,thatbesidesthepost-hoc
analysis, they have used unusual antihypertensive regimes,
which are seldom used in everyday clinical practice.
In the ASCOT trial, the combination of older drugs
(diuretics + beta blockers) was compared to newer drugs
(ACEinhibitors + calcium antagonists) [58]. In patients not
achieving blood pressure control, alpha blockers have been
added as third-line and spironolactone as fourth-line ther-
apy. It is obvious that some patients from the diuretic/beta
blockergroupmaybelabeled asresistant hypertensives when
the addition of alpha blockers was ineﬀective. It should be,
recognizedhowever,thatthecombinationofadiureticwitha
beta- andan alpha-blockeris uncommonin everydayclinical
practice. Calcium antagonists or agents acting on the renin-
angiotensin axis or a combination of both are used for the
vast majority of uncontrolled patients.
S i m i l a rp r o b l e m sa r ea p p l i c a b l et ot h eA C C O M P L I S H
trial, which compared the combination of an ACEinhibitor
with diuretics or calcium antagonists [59]. Uncontrolled
patientswereallowed touse betablockers.Therefore patients
from the ﬁrst group that remained uncontrolled with the
triple combination of ACEinhibitors, diuretics, and beta-
blockers can be characterized as resistant hypertensives
and be used as a source of valuable data extraction. This
combination is more clinically meaningful than the one used
in the ASCOT trial, even this, however, excludes the use of
calcium antagonists, which are among the most commonly
prescribed drugs in the western world for the treatment of
resistant hypertension.
The ALLHAT trial confronts similar problems. Patients
were assigned to receive diuretics, ACEinhibitors, calcium6 International Journal of Hypertension
antagonists, or alpha-blockers, and were allowed to use beta-
blockers,clonidine, or hydralazine in case the blood pressure
remained above goal [60]. Patients included in the diuretic
group that remained uncontrolled despite the use of two
additional drugs meet the criteria of resistant hypertension.
However, as one can easily notice, the drug combinations
that were actually used in this study are seldom used in
everyday clinical practice.
6.Conclusions
Data from large clinical trials in diﬀerent subgroups of
hypertensive patients suggest an increased prevalence of
resistant hypertension. Data regarding the risks of resistant
hypertension, as well as the beneﬁts oftreatment and control
of blood pressure in resistant hypertensive patients is scarce.
However, data from small clinical studies and observational
cohorts consistently points towards an increased cardiovas-
cular risk in patients with resistant hypertension. Moreover,
available information suggests that there is substantial
beneﬁt from appropriate treatment and control of resistant
patients. Recent randomized studies in resistant hyperten-
sion assessed theeﬃcacyand safety ofeithernewdrugs(such
as darusentan) [61, 62] or interventional techniques (such
as carotid baroreceptor stimulation or renal sympathetic
denervation) [63, 64]. We believe that appropriate large,
long-term studies are needed to evaluate the prevalence and
the risks of resistant hypertension, as well as the signiﬁcant
beneﬁts of treating and controlling resistant hypertension.
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